Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Last trade price

Icosavax Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Net Income
-91.76-66.97-18.85-5.97
Depreciation & Amortization
1.840.0800
Share-Based Compensation
21.6929.030.260.07
Other Operating Activities
6.55-0.684.390.66
Operating Cash Flow
-61.68-38.54-14.21-4.57
Capital Expenditures
-11.11-1.01-0.010
Change in Investments
-158.34000
Investing Cash Flow
-169.45-1.01-0.010
Share Issuance / Repurchase
10.31191.140.170.24
Debt Issued / Paid
006.460
Other Financing Activities
-113.63-26.5
Financing Cash Flow
10.31304.776.6426.74
Net Cash Flow
-220.82265.23-7.5822.17
Free Cash Flow
-72.79-39.55-14.22-4.57
Free Cash Flow Margin
-12506.53%-506.87%-879.89%-
Free Cash Flow Per Share
-1.83-2.20-6.33-0.69
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).